RESEARCH ARTICLE
Effect of Inhaled Corticosteroids on Glycemic Status
Francis Egbuonu 1, Farrah A Antonio 1, Mahamood Edavalath*, 2
Article Information
Identifiers and Pagination:
Year: 2014Volume: 8
First Page: 101
Last Page: 105
Publisher ID: TORMJ-8-101
DOI: 10.2174/1874306401408010101
Article History:
Received Date: 10/10/2014Revision Received Date: 21/10/2014
Acceptance Date: 21/10/2014
Electronic publication date: 31/12/2014
Collection year: 2014

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Although the dysglycemic effects of systemic glucocorticoid therapy are well known, the effect of inhaled corticosteroids (ICS) on carbohydrate metabolism is still a subject of debate. The systemic bioavailability of ICS is claimed to be minimal and the side effects negligible. However, some large retrospective cohort studies showed a definite association between ICS use and incident diabetes or worsening glycemic control in pre-existing diabetes. There are no professional-body recommended guidelines on the diagnosis and management of steroid-induced diabetes for the general population. This review aims to evaluate the systemic dysglycemic effect of ICS treatment and to propose a management algorithm.